newsfilter
← Latest News
GlobeNewswire·

NGM Bio's NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that the U.S. Fo